Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
14 mai 2020 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2020 Financial Results and Operational Updates
07 mai 2020 16h01 HE
|
Optinose, Inc.
Company reports first quarter 2020 XHANCE net revenue of $7.1 million First quarter 2020 XHANCE prescriptions increased 149% from first quarter 2019 Conference call and webcast to be held today at...
Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
30 avr. 2020 16h15 HE
|
Optinose, Inc.
Conference Call and Webcast Scheduled for Thursday, May 7 at 4:15 p.m. Eastern Time YARDLEY, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
05 mars 2020 06h30 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2019 XHANCE net revenue of $11.1 million and $30.4 million Fourth quarter 2019 XHANCE prescriptions increased 26% from third quarter 2019 Company expects...
Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
27 févr. 2020 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Victor Clavelli as Chief Commercial Officer
19 févr. 2020 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
17 déc. 2019 08h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference
26 nov. 2019 16h01 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
21 nov. 2019 09h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Proposed Public Offering of Common Stock
20 nov. 2019 16h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...